Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathies

被引:46
作者
Livshits, G. [1 ]
Kalinkovich, A. [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, Human Populat Biol Res Unit, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Rheumatoid arthritis; Spondyloarthritis; Osteoarthritis; Disc degenerative disease; Inflammation; Cytokine network; NECROSIS-FACTOR-ALPHA; POTENTIAL THERAPEUTIC AGENT; RHEUMATOID-ARTHRITIS; TNF-ALPHA; SYNOVIAL-FLUID; DIFFERENTIAL EXPRESSION; CLINICAL-SIGNIFICANCE; PSORIATIC-ARTHRITIS; DISC DEGENERATION; MASTER REGULATOR;
D O I
10.1016/j.joca.2017.10.013
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Chronic inflammatory arthropathies, such as rheumatoid arthritis (RA), spondyloarthritis, including psoriatic arthritis (PsA), ankylosing spondyloarthritis (AS), osteoarthritis (OA), and intervertebral disc degenerative disease (DDD) constitute major public health problems that are anticipated to grow significantly as the human population ages. However, many aspects concerning the molecular mechanisms underlying their onset and progression remain unclear. Design: This narrative review critically analyzes the molecular mechanisms underlying the inflammation-associated pathogenesis of the aforementioned joint diseases. This includes, in particular, the major role played by several key soluble factors (such as cytokines and the associated signaling pathways, designated as "fragile nodes") produced by local cells and recruited to the joints' immune cells, whose elimination by specific drugs has dramatically improved the diseases' symptomatology and outcome in human clinical trials or in rodent arthritis models. Hypothesis and the aim of this review: We hypothesize that the pathogenesis of chronic inflammatory arthropathies is governed by hierarchical, imbalanced pro-inflammatory cytokine networks (HIPICNs) (comprising a combination of fragile nodes) that are created during the development of both autoimmune (RA, PsA, and AS) and non-autoimmune (OA and DDD) disorders. The main aim of this review is to provide evidence that despite substantial pathobiological differences between these arthropathies, the HIPICNs created are quite common, thus justifying the merging of these disorders mechanistically and suggesting that these common mechanisms exist in the onset and progression of different joint diseases. (c) 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 94 条
[1]   The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis [J].
Addimanda, Olga ;
Possemato, Niccolo ;
Caruso, Andrea ;
Pipitone, Nicolo ;
Salvarani, Carlo .
JOURNAL OF RHEUMATOLOGY, 2015, 42 :73-78
[2]   JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects [J].
Banerjee, Shubhasree ;
Biehl, Ann ;
Gadina, Massimo ;
Hasni, Sarfaraz ;
Schwartz, Daniella M. .
DRUGS, 2017, 77 (05) :521-546
[3]   Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts [J].
Baum, Rebecca ;
Gravallese, Ellen M. .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2016, 51 (01) :1-15
[4]   Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!) [J].
Berenbaum, F. .
OSTEOARTHRITIS AND CARTILAGE, 2013, 21 (01) :16-21
[5]  
Bocian K, 2017, ARCH IMMUNOL THER EX
[6]   The role of cytokines in the pathogenesis of rheumatoid arthritis - Practical and potential application of cytokines as biomarkers and targets of personalized therapy [J].
Brzustewicz, Edyta ;
Bryl, Ewa .
CYTOKINE, 2015, 76 (02) :527-536
[7]   The Paracrine Effect of Degenerated Disc Cells on Healthy Human Nucleus Pulposus Cells Is Mediated by MAPK and NF-κB Pathways and Can Be Reduced by TGF-β1 [J].
Cai, Feng ;
Zhu, Lei ;
Wang, Feng ;
Shi, Rui ;
Xie, Xin-Hui ;
Hong, Xin ;
Wang, Xiao-Hu ;
Wu, Xiao-Tao .
DNA AND CELL BIOLOGY, 2017, 36 (02) :143-158
[8]   Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [J].
Cantini, Fabrizio ;
Niccoli, Laura ;
Nannini, Carlotta ;
Cassara, Emanuele ;
Kaloudi, Olga ;
Favalli, Ennio Giulio ;
Becciolini, Andrea ;
Benucci, Maurizio ;
Gobbi, Francesca Li ;
Guiducci, Serena ;
Foti, Rosario ;
Mosca, Marta ;
Goletti, Delia .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) :183-192
[9]   Emerging drugs for psoriatic arthritis [J].
Caso, Francesco ;
Del Puente, Antonio ;
Peluso, Rosario ;
Caso, Paolo ;
Girolimetto, Nicolo ;
Del Puente, Aurora ;
Scarpa, Raffaele ;
Costa, Luisa .
EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) :69-79
[10]   Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis [J].
Chiu, Yahui Grace ;
Ritchlin, Christopher T. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (01) :119-128